Artios Pharma headquarters details
- City
- Cambridge
- State / region
- England
- ZIP / postal code
- cb22 3fh
- Country
- United Kingdom
- Phone
- +44 1223 804180
- Founded
- 2015
- Website
- artios.com
Location map
Open in Google MapsAll Artios Pharma office locations
| City | State / region | Country | Type |
|---|---|---|---|
| Cambridge HQ | England | United Kingdom | Headquarters |
Showing the headquarters of 6 recorded locations. See every location in GraphIQ →
About Artios Pharma
Artios Pharma is headquartered in Cambridge, England, United Kingdom. Founded in 2015, the company has 6 recorded locations across 2+ countries and employs approximately 128 people worldwide.
Where is Artios Pharma's main office?
Artios Pharma's main headquarters office is located at Cambridge, England cb22 3fh, United Kingdom. This is the company's primary corporate address.
Artios Pharma regional offices
Beyond its headquarters in Cambridge, Artios Pharma has recorded locations in United Kingdom and United States.
Artios Pharma contact information
The main switchboard for Artios Pharma headquarters can be reached at +44 1223 804180. Official website: artios.com.
What does Artios Pharma do?
Artios Pharma Limited operates as a biotechnology company. The Company develops cancer treatments that target DNA damage response (DDR) pathway to tackle certain devastating cancers that are difficult to treat. Artios Pharma offers its services in the United Kingdom.
Frequently asked questions
Where is Artios Pharma headquarters?
Artios Pharma's headquarters is located at Cambridge, England cb22 3fh, United Kingdom.
How many offices does Artios Pharma have?
GraphIQ records 6 locations for Artios Pharma across 2+ countries, as of October 2026.
When was Artios Pharma founded?
Artios Pharma was founded in 2015 and employs approximately 128 people.
What is Artios Pharma's phone number?
The main phone number for Artios Pharma headquarters is +44 1223 804180.
How many employees does Artios Pharma have?
Artios Pharma has approximately 128 employees (GraphIQ estimate, 2026).